GemPharmatech Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	876.25	792.67	686.28	621.73	515.67	392.44
Other Revenue	1.88	0.72	0.56	0.45	0.87	1.34
Revenue	878.13	793.39	686.84	622.19	516.55	393.79
Revenue Growth	21.75%	15.51%	10.39%	20.45%	31.17%	50.35%
Cost of Revenue	320.04	288.94	261.33	202.86	150.22	101.27
Gross Profit	558.09	504.45	425.51	419.33	366.33	292.51
Selling, General & Admin	256.34	246.04	239.68	199.61	174.76	134.42
Research & Development	98.58	92.06	87.13	96.6	82.93	55.2
Other Operating Expenses	10.45	4.38	3.57	2.61	1.72	1.59
Operating Expenses	370.45	352.17	333.68	307.91	267.94	196.11
Operating Income	187.64	152.28	91.83	111.42	98.39	96.4
Interest Expense	-6.29	-6.08	-4.3	-2.76	-0.5	-0.74
Interest & Investment Income	28.89	19.31	22.39	28.65	23.73	14.43
Currency Exchange Gain (Loss)	-8.71	-0.91	1.69	0.08	1.49	-0.19
Other Non Operating Income (Expenses)	-12.83	-15.64	-21.56	-20.92	-11.32	-16.05
EBT Excluding Unusual Items	188.71	148.96	90.06	116.48	111.8	93.84
Gain (Loss) on Sale of Investments	1.25	0.69	2.34	2.73	-0.05	0.32
Gain (Loss) on Sale of Assets	-0.01	-0.04	0.01	-0.02	-0.1	0.05
Other Unusual Items	21.81	15.3	26.8	42.1	62.03	49.1
Pretax Income	211.75	164.92	119.22	161.29	173.68	143.31
Income Tax Expense	29.2	22.29	9.4	2.37	9.02	18.39
Earnings From Continuing Operations	182.55	142.64	109.82	158.91	164.67	124.93
Net Income	182.55	142.64	109.82	158.91	164.67	124.93
Net Income to Common	182.55	142.64	109.82	158.91	164.67	124.93
Net Income Growth	74.87%	29.88%	-30.89%	-3.49%	31.81%	63.45%
Shares Outstanding (Basic)	404	408	407	407	392	357
Shares Outstanding (Diluted)	404	408	407	407	392	357
Shares Change	-2.46%	0.19%	-0.18%	3.93%	9.84%	-1.93%
EPS (Basic)	0.45	0.35	0.27	0.39	0.42	0.35
EPS (Diluted)	0.45	0.35	0.27	0.39	0.42	0.35
EPS Growth	79.29%	29.63%	-30.77%	-7.14%	20.00%	66.67%

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	230.4	122.04	-23.36	-89.33	-84.33	24.24
Free Cash Flow Per Share	0.57	0.30	-0.06	-0.22	-0.21	0.07
Dividend Per Share	0.320	0.220	0.140	0.160	0.041	-
Dividend Growth	128.57%	57.14%	-12.50%	290.24%	-	-
Gross Margin	63.55%	63.58%	61.95%	67.40%	70.92%	74.28%
Operating Margin	21.37%	19.19%	13.37%	17.91%	19.05%	24.48%
Profit Margin	20.79%	17.98%	15.99%	25.54%	31.88%	31.72%
Free Cash Flow Margin	26.24%	15.38%	-3.40%	-14.36%	-16.33%	6.16%
EBITDA	264.12	225.7	165.73	157.42	135.68	125.2
EBITDA Margin	30.08%	28.45%	24.13%	25.30%	26.27%	31.80%
D&A For EBITDA	76.48	73.42	73.9	46	37.29	28.81
EBIT	187.64	152.28	91.83	111.42	98.39	96.4
EBIT Margin	21.37%	19.19%	13.37%	17.91%	19.05%	24.48%
Effective Tax Rate	13.79%	13.51%	7.88%	1.47%	5.19%	12.83%
Revenue as Reported	878.13	793.39	686.84	622.19	516.55	393.79
Advertising Expenses	-	1.78	2.93	4.69	8.94	2.87